Healthcare / BiotechnologyNasdaqCM
$1.99
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-27.5M · quality 53.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
1/100
F
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$29M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-393.9%
↓Gross Margin
N/A
•Debt/Equity
N/A
•Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2011–2025 · 14 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
1.02x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-26.3M · FCF $-26.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||||||
| Revenue | — | — | — | — | — | — | — | — | — | $295000.00 | $653000.00 | $277000.00 | $0.00 | $0.00 | — | — |
| Net Income | $-26.3M | $-26.3M | $-41.8M | $-29.5M | $-35.7M | $-28.3M | $-19.2M | $-44.6M | $-27.2M | $-84.6M | $-82.3M | $-73.2M | $-49.5M | $-29.0M | $-13.5M | — |
| EBITDA | — | — | — | — | — | — | — | — | — | $-82.7M | $-78.8M | $-70.7M | $-47.5M | $-28.9M | $-13.4M | — |
| EPS | -6.33 | -6.33 | -19.50 | -1.91 | -3.09 | -7.47 | -41.03 | — | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — | — | -28585.1% | -12406.1% | -25992.4% | — | — | — | — |
| Net Margin | — | — | — | — | — | — | — | — | — | -28670.5% | -12597.2% | -26432.9% | — | — | — | — |
| Balance Sheet | ||||||||||||||||
| Debt/Equity | — | — | 0.00 | 0.23 | 0.57 | 0.42 | -0.00 | -0.00 | 0.01 | -0.00 | — | — | — | — | — | — |
| Cash Flow | ||||||||||||||||
| Free Cash Flow | $-26.8M | $-26.8M | $-33.5M | $-27.5M | $-31.6M | $-26.1M | $-19.1M | $-41.6M | $-23.7M | $-20.3M | $-64.3M | $-55.5M | $-33.4M | $-18.8M | — | — |
| Returns | ||||||||||||||||
| ROE | -393.9% | -393.9% | -218.8% | -110.2% | -197.2% | -78.4% | 27.9% | 88.5% | -38.3% | 64.7% | -76.0% | -57.7% | -89.5% | -69.6% | -44.0% | — |
| Growth & Yield | ||||||||||||||||
| Revenue Growth | — | — | — | — | — | — | — | — | — | -54.8% | 135.7% | — | — | — | — | — |
| EPS Growth | 67.5% | 67.5% | -920.9% | 38.2% | 58.6% | 81.8% | — | — | — | — | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Unavailable: positive start/end prices are required.